Publications
PrecivityAD® and PrecivityAD2™ Tests - Research & Trials
Impact on Clinical Trial Enrollment, Design and Economics
Walter S, Langford O, Jimenez-Maggiora GA, et al. The AlzMatch Pilot Study - Feasibility of remote blood collection of plasma biomarkers for preclinical Alzheimer’s disease trials. J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi.org/10.14283/jpad.2024.101
Angioni D, Hansson O, Bateman RJ, et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2023;10(3):418-425. doi.org/10.14283/jpad.2023.68
Schindler SE, Li Y, Li M, et al. Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment. Alzheimer’s Dement. 2023;19(4):1175-1183. doi:10.1002/alz.12754
Amyloid Accumulation Over Time
Milà-Alomà M, Tosun D, Schindler SE, et al. Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks. Ann Neurol. Published online June 20, 2025. doi:10.1002/ana.27285
Cogswell PM, Wiste HJ, Weigand SD, et al. Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET. Alzheimer’s Dement. 2025;21(2):e14629. doi:10.1002/alz.14629
Li Y, Yen D, Hendrix RD, et al. Timing of biomarker changes in sporadic Alzheimer disease in estimated years from symptom onset. Ann Neurol. 2024;95:951-965. doi:10.1002/ana.26891
Analyte Performance
Palmqvist S, Warmenhoven N, Anastasi F, et al. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. Published online April 9, 2025. doi:10.1038/s41591-025-03622-w
Cody KA, Du L, Studer RL, et al. Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia. Alzheimers Dement. 2025;21(3):e14570. doi:10.1002/alz.14570
Bornhorst JA, Lundgreen CS, Weigand SD, et al. Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations. Neurology. 2025;104(3):e210287. doi:10.1212/WNL.0000000000210287
Devanarayan V, Charil A, Horie K, et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease. Alzheimer's Dement. 2024;1-15. doi:10.1002/alz.14411
Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. Alzheimer’s Dement. 2024;20:8074–8096. doi:10.1002/alz.143
Devanarayan V, Doherty T, Charil A, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer’s Dement. 2024;20(8):5617-5628. doi:10.1002/alz.14073
Meeker KL, Luckett PH, Barthélemy NR, et al. Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Commun. 2024;6(2):fcae081. doi:10.1093/braincomms/fcae081
Bayat S, Roe CM, Schindler S, et al. Everyday driving and plasma biomarkers in Alzheimer's Disease: Leveraging artificial intelligence to expand our diagnostic toolkit. J Alzheimers Dis. 2023;92(4):1487-1497. doi:10.3233/JAD-221268
Wisch J, Gordon B, Boerwinkle A, et al. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. Alzheimer’s Dement. 2023;15(1):e12405. doi:10.1002/dad2.12405
Hartz SM, Mozersky J, Schindler SE, et al. A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer’s disease dementia. Alzheimer’s Dement. 2022;19(4):1452-1465. doi:10.1002/alz.12781
Winston CN, Langford O, Levin N, et al. Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s disease. J Alzheimers Dis. 2023; 92(1), 95–107. doi.org/10.3233/JAD-221118
Aschenbrenner AJ, Li Y, Henson RL, et al. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol 2022; 9(11):1739-1751. doi:10.1002/acn3.51670
Treatment Monitoring (Research Use)
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.202313239
Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19(4):1227-1233. doi:10.1002/alz.12748
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191. doi:10.1186/s13195-022-01124-2
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody [published correction appears in Alzheimers Res Ther. 2022 May 21;14(1):70]. Alzheimers Res Ther. 2021;13(1):80. doi:10.1186/s13195-021-00813-8
* Publication includes Precivity-p-tau217 analyte measurements (part of PrecivityAD2 rather than PrecivityAD) used in longitudinal monitoring